Skip to main content
Signal8

Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing

$GILDPress releaseNov 16, 2026, 4:05 PM ETRead the release

Gilead signed royalty-free voluntary licensing agreements with three generic manufacturers — Dr. Reddy's, Eva Pharma and Ferozsons — for investigational obeldesivir as post-exposure prophylaxis for Ebola Bundibugyo virus disease across 127 primarily low- and lower-middle-income countries. The agreements were signed in advance of results from the Phase 3 EBO-PEP field trial and any regulatory submissions, and cover all African countries reporting cases in the current outbreak. Gilead is also expanding its existing remdesivir voluntary licenses to include filovirus disease.

Key figures

Licensed countries
127
Generic manufacturers
3
Remdesivir vials donated kenya
more than 2,000
Remdesivir vials donated total
more than 38,000

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.